chloroquine has been researched along with Rheumatism in 111 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chronic use of chloroquine and hydroxychloroquine inthe treatment of rheumatic disease carries a small risk of sight-threatening pigmentary retinopathy." | 7.71 | Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. ( Buncic, RJ; Ito, S; Klinger, G; Koren, G; Laskin, C; Morad, Y; Spitzer, KA; Westall, CA, 2001) |
| " Pharmacokinetic interaction studies are limited." | 6.39 | Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ( Furst, DE, 1996) |
| "To check the ability of microperimetry to detect early retinal damage in patients with rheumatism taking hydroxychloroquine (HCQ), chloroquine (CQ), or both, and to describe the microperimetric alterations attributable to these drugs and their correlation with some clinical variables." | 5.17 | Use of microperimetry to evaluate hydroxychloroquine and chloroquine retinal toxicity. ( Beltrán-Catalán, E; Epifanio, I; Marco-Ventura, P; Martínez-Costa, L; Murcia-Bello, C; Verdejo-Gimeno, C; Victoria Ibañez, M, 2013) |
| "Hydroxychloroquine and quinacrine are frequently used to treat rheumatic diseases." | 5.01 | Are the Current Recommendations for Chloroquine and Hydroxychloroquine Screening Appropriate? ( Samson, CM; Schwartzman, S, 2019) |
| "The antimalarial drugs chloroquine (CQ) and hydroxychloroquine (HCQ) have been used for decades to treat rheumatic diseases." | 4.87 | Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature. ( Koren, G; Osadchy, A; Ratnapalan, T, 2011) |
| " D-Penicillamine may be teratogenic thus it should not be commenced during pregnancy and if a patient becomes pregnant whilst receiving the drug, it should be slowly withdrawn or the dosage reduced." | 4.77 | Antirheumatic medication in pregnancy. ( Brooks, PM; Needs, CJ, 1985) |
| "The study was based on a group of 152 patients with rheumatic diseases, aged 20-78 years, treated either with chloroquine or hydroxychloroquine." | 4.02 | Chloroquine and hydroxychloroquine - safety profile of potential COVID-19 drugs from the rheumatologist's perspective. ( Grygiel-Górniak, B; Majewska, KA; Majewski, D; Naskręcka, M, 2021) |
| "Chronic use of chloroquine and hydroxychloroquine inthe treatment of rheumatic disease carries a small risk of sight-threatening pigmentary retinopathy." | 3.71 | Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. ( Buncic, RJ; Ito, S; Klinger, G; Koren, G; Laskin, C; Morad, Y; Spitzer, KA; Westall, CA, 2001) |
| "Specific information concerning the use of nonsteroidal anti-inflammatory agents, salicylates, analgesics, remittive drugs, and other adjunctive treatments used for rheumatic diseases are addressed." | 3.67 | The use of drugs in rheumatic diseases. ( Gall, EP, 1984) |
| " During treatment with the basic drugs: gold, D-penicillamine and chloroquine, pregnancy should be avoided." | 3.65 | [Problems of rheumatic therapy in pregnancy (author's transl)]. ( Bischof, P, 1976) |
| "Antimalarial drugs including chloroquine, its less toxic quinolone-derivative hydroxychloroquine (HCQ), and quinacrine have become cornerstones in the treatment of autoimmune diseases including systemic lupus, rheumatoid arthritis, sarcoidosis, and Sjogren syndrome; cutaneous disorders, antiphospholipid syndrome, and have recently been employed at higher dioses in oncology." | 2.58 | Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update. ( Abdulaziz, N; McCune, WJ; Shah, AR, 2018) |
| " Pharmacokinetic interaction studies are limited." | 2.39 | Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ( Furst, DE, 1996) |
| " Taken together, these data suggest that more effective dosage regimens will be possible when therapeutic concentration ranges are properly established." | 2.38 | Antimalarials in rheumatic diseases. ( Cutler, D; Day, R; Tett, S, 1990) |
| "With the exception of the treatment of gout and bacterial infections of joints, therapy in the rheumatic diseases remains inadequate." | 2.36 | Antirheumatic drugs: clinical pharmacology and therapeutic use. ( Buchanan, WW; Craig, GL, 1980) |
| " Depression of extra-oculogram is an early sign of excessive dosage and can be used to measure potential toxicity during therapy with 4-aminoquinolines." | 1.27 | Pharmacologic actions of 4-aminoquinoline compounds. ( Mackenzie, AH, 1983) |
| " Currently recommended dosage schedules appear to be too high in certain cases." | 1.27 | Steady state disposition of chloroquine in patients with rheumatoid disease. ( Bergqvist, Y; Domeij-Nyberg, B; Frisk-Holmberg, M, 1983) |
| " The present knowledge of CQ kinetics could provide a basis for revision of current dosage regimens in malaria suppression and rheumatoid disease to ensure efficacious and safe therapy." | 1.27 | The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects. ( Bergqvist, Y; Domeij-Nyberg, B; Frisk-Holmberg, M; Termond, E, 1984) |
| "Causal therapy of rheumatic diseases is only possible in the few cases of bacterial infection and some arthroses." | 1.26 | [Guidelines to the therapie of the most important rheumatic diseases (author's transl)]. ( Heimstädt, P, 1977) |
| " Chloroquine displayed dose-dependent kinetics, which may indicate that close monitoring of serum concentrations is an aid to the safe and rational use of the drug." | 1.26 | Chloroquine serum concentration and side effects: evidence for dose-dependent kinetics. ( Bergkvist, Y; Domeij-Nyberg, B; Frisk-Holmberg, M; Hellström, L; Jansson, F, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 81 (72.97) | 18.7374 |
| 1990's | 8 (7.21) | 18.2507 |
| 2000's | 6 (5.41) | 29.6817 |
| 2010's | 8 (7.21) | 24.3611 |
| 2020's | 8 (7.21) | 2.80 |
| Authors | Studies |
|---|---|
| Ntshalintshali, SD | 1 |
| Geldenhuys, EM | 1 |
| Moosajee, F | 1 |
| Musa, WAM | 1 |
| Du Plessis, L | 1 |
| Viljoen, A | 1 |
| Fortuin, D | 1 |
| Du Toit, R | 1 |
| Yazdany, J | 1 |
| Kim, AHJ | 1 |
| Marotto, D | 1 |
| Sarzi-Puttini, P | 1 |
| Licciardi, F | 1 |
| Giani, T | 1 |
| Baldini, L | 1 |
| Favalli, EG | 1 |
| Caporali, R | 1 |
| Cimaz, R | 1 |
| Kucharz, EJ | 1 |
| Hodkinson, B | 1 |
| Singh, P | 1 |
| Gcelu, A | 1 |
| Bautista-Molano, W | 1 |
| Pons-Estel, G | 1 |
| Alpízar-Rodríguez, D | 1 |
| Murray, K | 1 |
| Quinn, S | 1 |
| Turk, M | 1 |
| O'Rourke, A | 1 |
| Molloy, E | 1 |
| O'Neill, L | 1 |
| Mongey, AB | 1 |
| Fearon, U | 1 |
| Veale, DJ | 1 |
| Majewski, D | 1 |
| Majewska, KA | 1 |
| Naskręcka, M | 1 |
| Grygiel-Górniak, B | 1 |
| Martí-Carvajal, A | 1 |
| Ramon-Pardo, P | 1 |
| Javelle, E | 1 |
| Simon, F | 1 |
| Aldighieri, S | 1 |
| Horvath, H | 1 |
| Rodriguez-Abreu, J | 1 |
| Reveiz, L | 1 |
| Yogasundaram, H | 1 |
| Hung, W | 1 |
| Paterson, ID | 1 |
| Sergi, C | 1 |
| Oudit, GY | 1 |
| Abdulaziz, N | 1 |
| Shah, AR | 1 |
| McCune, WJ | 1 |
| Schwartzman, S | 1 |
| Samson, CM | 1 |
| Martínez-Costa, L | 1 |
| Victoria Ibañez, M | 1 |
| Murcia-Bello, C | 1 |
| Epifanio, I | 1 |
| Verdejo-Gimeno, C | 1 |
| Beltrán-Catalán, E | 1 |
| Marco-Ventura, P | 1 |
| Katz, SJ | 1 |
| Russell, AS | 4 |
| Osadchy, A | 1 |
| Ratnapalan, T | 1 |
| Koren, G | 2 |
| Missner, S | 1 |
| Kellner, U | 1 |
| Schiemann, U | 1 |
| Kellner, H | 1 |
| Abud-Mendoza, C | 1 |
| de la Fuente, H | 1 |
| Cuevas-Orta, E | 1 |
| Baranda, L | 1 |
| Cruz-Rizo, J | 1 |
| González-Amaro, R | 1 |
| BAGNALL, AW | 1 |
| ROUSSEAU, J | 1 |
| GUNTHER, R | 1 |
| BARWIK-SCHRAMM, A | 1 |
| SCHRAMM, AB | 1 |
| MERKEL, G | 1 |
| WINER, J | 1 |
| REICHER, E | 1 |
| DUBROWSKA, D | 1 |
| GERHARDT, HJ | 1 |
| HEIDE, M | 1 |
| WHITEHOUSE, MW | 1 |
| RYCKEWAERT, A | 1 |
| KAHN, MF | 1 |
| DEBEYRE, N | 1 |
| BARWIK-SCHRAM, A | 1 |
| SOKOLOWSKI, A | 1 |
| NIEWEG, HO | 1 |
| BOUMA, HG | 1 |
| DEVRIES, K | 1 |
| JANSZ, A | 1 |
| BIBIKOVA, TI | 1 |
| SIGIDIN, IaA | 2 |
| DELACHAUX, A | 1 |
| TAKAGISHI, N | 1 |
| TAMARU, T | 1 |
| KITSUKAWA, M | 1 |
| KUNIKISA, Y | 1 |
| OTANI, T | 1 |
| HENKIND, P | 2 |
| MORETTINI, A | 1 |
| MORACE, G | 1 |
| PANERAI, A | 1 |
| GHETTI, A | 1 |
| CORRADI, F | 1 |
| BERNACKA, K | 1 |
| KOSSAKOWSKI, D | 1 |
| KAZIOR, A | 1 |
| KERUZORE, A | 1 |
| COSTE, F | 1 |
| DELBARRE, F | 1 |
| LEGEAIS, G | 1 |
| PIOTROWSKI, J | 1 |
| SABATINI, R | 1 |
| LOUYOT, P | 1 |
| GAUCHER, A | 1 |
| MATHIEU, J | 1 |
| METZ, R | 1 |
| OTTO, W | 1 |
| TAUTENHAHN, B | 1 |
| Araiza-Casillas, R | 1 |
| Cárdenas, F | 1 |
| Morales, Y | 1 |
| Cardiel, MH | 1 |
| Easterbrook, M | 1 |
| Casado, E | 1 |
| Gratacós, J | 1 |
| Tolosa, C | 1 |
| Martínez, JM | 1 |
| Ojanguren, I | 1 |
| Ariza, A | 1 |
| Real, J | 1 |
| Sanjuán, A | 1 |
| Larrosa, M | 1 |
| Hoza, J | 1 |
| Rubín, A | 1 |
| Fink, Z | 1 |
| Havelka, S | 1 |
| Gall, EP | 1 |
| Bjelle, A | 1 |
| Mjörndal, T | 1 |
| Mackenzie, AH | 1 |
| Frisk-Holmberg, M | 3 |
| Bergqvist, Y | 2 |
| Domeij-Nyberg, B | 3 |
| Termond, E | 1 |
| Orme, ML | 1 |
| Mariani, L | 1 |
| Baratelli, M | 1 |
| Hunneyball, IM | 1 |
| Craig, GL | 1 |
| Buchanan, WW | 1 |
| Hellgren, U | 1 |
| Alván, G | 1 |
| Jerling, M | 1 |
| Cutler, DJ | 1 |
| Fox, R | 1 |
| Furst, DE | 1 |
| Rynes, RI | 1 |
| Aviña-Zubieta, JA | 1 |
| Galindo-Rodriguez, G | 1 |
| Newman, S | 1 |
| Suarez-Almazor, ME | 1 |
| Klinger, G | 1 |
| Morad, Y | 1 |
| Westall, CA | 1 |
| Laskin, C | 1 |
| Spitzer, KA | 1 |
| Ito, S | 1 |
| Buncic, RJ | 1 |
| Schönhöfer, PS | 1 |
| Mathies, H | 4 |
| Holt, PJ | 1 |
| Meyer, W | 1 |
| Weyerbrock, W | 1 |
| Heimstädt, P | 1 |
| Tarayre, JP | 1 |
| Delhon, A | 1 |
| Lauressergues, H | 1 |
| Bischof, P | 2 |
| Kaiser, H | 1 |
| Bergkvist, Y | 1 |
| Hellström, L | 1 |
| Jansson, F | 1 |
| Evens, RP | 1 |
| Miehlke, K | 1 |
| Nordemar, R | 1 |
| Bresloff, P | 1 |
| Shalumashvili, MA | 1 |
| Golding, DN | 1 |
| Youssef, W | 1 |
| Yan, A | 1 |
| Tett, S | 1 |
| Cutler, D | 1 |
| Day, R | 1 |
| Davidovskiĭ, LIa | 1 |
| Landsman, FI | 1 |
| Bisengalieva, US | 1 |
| Lopatkova, LM | 1 |
| Richardson, MR | 1 |
| Zalin, AM | 1 |
| Hanonen, P | 1 |
| Möttönen, T | 1 |
| Oka, M | 1 |
| Dugowson, CE | 1 |
| Gilliland, BC | 1 |
| Maksymowych, W | 1 |
| Ostensen, M | 1 |
| Husby, G | 1 |
| Needs, CJ | 1 |
| Brooks, PM | 1 |
| Gold, DH | 1 |
| Böke, W | 1 |
| Boden, BF | 1 |
| Bach, GL | 1 |
| Rix, R | 1 |
| Mayer, U | 1 |
| Stancìkovà, M | 1 |
| Trnavsky, K | 1 |
| Kelsey, JH | 1 |
| Mirić, V | 1 |
| Tomasević, M | 1 |
| Rothermich, NO | 1 |
| Missmahl, HP | 1 |
| Mayr, E | 1 |
| Santos, Oda R | 1 |
| Houli, J | 1 |
| Rölke, HW | 1 |
| Schuster, E | 1 |
| Nowicki, NJ | 1 |
| Lendle, L | 1 |
| Gamp, A | 1 |
| Schilling, A | 1 |
| Ruiz, SI | 1 |
| Cobra, CJ | 1 |
| Bouvenot, G | 1 |
| Vykydal, M | 1 |
| Adams, SS | 1 |
| Hauschild, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss ,Double Blinded Randomized Controlled Trial .[NCT05237843] | Phase 1 | 70 participants (Anticipated) | Interventional | 2022-03-01 | Not yet recruiting | ||
| A Double Blind, Placebo Controlled, Phase II, Randomized Study of Lovastatin Therapy in the Treatment of Mildly Active Rheumatoid Arthritis[NCT00302952] | Phase 2 | 64 participants (Actual) | Interventional | 2007-11-06 | Terminated (stopped due to Slow enrollment &Study Drug Expiration (Target: 40 randomized participants /arm)) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Blood draw for CRP, an acute phase reactant used to identify the presence of nonspecific inflammation. Change=Day 84 value minus Baseline value. Normal serum CRP reference range in this study is 0-4 mg/L (log transformed: -4.2 to 1.4). Participants with measurements for designated time points were included in analysis. An increased CRP level indicates the presence of inflammation. Reduced CRP levels could mean a decrease in inflammation. (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
| Intervention | mg/L (Mean) |
|---|---|
| Lovastatin 80 mg | -0.4 |
| Placebo | -0.3 |
Anti-CCP antibodies are autoantibodies frequently detected in the serum of individuals with rheumatoid arthritis. In this study, a positive value for anti-CCP was 8 IU/mL or greater; a negative value for anti-CCP was <8 IU/mL. Change= subtraction of Day 0 from Day 84 anti-CCP value. In general, high levels of the antibody indicate an aggressive rheumatoid arthritis and a higher risk of joint damage. Participants with measurements for designated time points included in analysis. (NCT00302952)
Timeframe: Baseline ( Day 0), Day 84 (Wk 12)
| Intervention | IU/mL (Mean) |
|---|---|
| Lovastatin 80 mg | 16.3 |
| Placebo | -1.0 |
Rheumatoid factor (RF) is an antibody often present in the blood of a person with rheumatoid arthritis. In this study, a positive value for RF was 0.5 IU/mL or greater; a negative value for RF was <0.5 IU/mL. Change= Day 84 value minus Baseline value. In general, presence of the antibody indicates aggressive rheumatoid arthritis and higher risk of joint damage. Participants with measurements for designated time points included in analysis. (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
| Intervention | IU/mL (Mean) |
|---|---|
| Lovastatin 80 mg | -5.4 |
| Placebo | 2.8 |
The DAS28-CRP score is on a scale of 0 to 10 and indicates current activity of rheumatoid arthritis (>5.1=high disease activity; 3.2-<=5.1=moderate disease activity; <=3.2=low disease activity; <2.6=remission). The score uses a combination of four variables: 1) the number of tender joints (of the 28 that are measured); 2) the number of swollen joints (of the 28 that are measured); 3) serum C-reactive protein (CRP) lab value in mg/L , and 4) Patient Global Assessment of Disease Activity. Using a formula, the physician determines the score. Participants with measurements for designated time points included in analysis. (NCT00302952)
Timeframe: Baseline (Day 0) to Day 84 (Wk 12)
| Intervention | Scores on a scale (Mean) |
|---|---|
| Lovastatin 80 mg | -0.5 |
| Placebo | -0.5 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
| Intervention | U/L (Mean) |
|---|---|
| Lovastatin 80 mg | -2.4 |
| Placebo | 8.0 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
| Intervention | % of packed red blood cells by volume (Mean) |
|---|---|
| Lovastatin 80 mg | -0.5 |
| Placebo | -0.5 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
| Intervention | pg (Mean) |
|---|---|
| Lovastatin 80 mg | -0.4 |
| Placebo | 0.0 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
| Intervention | fL (Mean) |
|---|---|
| Lovastatin 80 mg | -0.4 |
| Placebo | 0.7 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
| Intervention | % of mean corpuscle volume (Mean) |
|---|---|
| Lovastatin 80 mg | -0.4 |
| Placebo | 0.2 |
Patients were ACR20 Responders if they had: at least 20% improvement in both tender joint count (28 examined) and swollen joint count (28 examined), and 20% improvement in at least three of the following 5 remaining ACR core measures: • Patient's pain assessment (Visual Analogue Scale (VAS) 100 mm) • Patient's global assessment of disease activity (VAS 100 mm) • Physician's global assessment of disease activity (VAS 100 mm) • Patient self-assessed disability (Health Assessment Questionnaire (HAQ)) score • Acute phase reactant C-reactive protein. Participants with measurements for designated time points were included in analysis. (NCT00302952)
Timeframe: Day 84 (Wk 12)
| Intervention | Percentage of participants (Number) |
|---|---|
| Lovastatin 80 mg | 29.0 |
| Placebo | 40.0 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
| Intervention | g/dL (Mean) | |||
|---|---|---|---|---|
| Albumin | Total Protein | Hemoglobin | MCHC | |
| Lovastatin 80 mg | 0.0 | 0.0 | -0.3 | -0.3 |
| Placebo | 0.1 | 0.1 | -0.3 | -0.4 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
| Intervention | U/L (Mean) | ||
|---|---|---|---|
| Alkaline Phosphatase | ALT | AST | |
| Lovastatin 80 mg | -3.0 | -1.8 | -1.2 |
| Placebo | 0.4 | 0.7 | 0.8 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
| Intervention | 10^3/uL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| WBC | Neutrophils | Bands | Lymphocytes | Monocytes | Eosinophils | Basophils | Platelet Count | Reticulocytes | |
| Lovastatin 80 mg | 0.1 | 0.2 | 0.0 | -0.1 | 0.1 | 0.0 | 0.0 | -8.2 | -4.7 |
| Placebo | -0.4 | -0.6 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | -5.6 | 0.0 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
| Intervention | mmol/L (Mean) | |||
|---|---|---|---|---|
| Potassium | Sodium | Chloride | Total CO2 | |
| Lovastatin 80 mg | 0.0 | -0.2 | -0.1 | 0.7 |
| Placebo | 0.0 | -0.2 | 0.5 | -0.5 |
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)
| Intervention | mg/dL (Mean) | |||||
|---|---|---|---|---|---|---|
| Total Bilirubin | Creatinine | BUN | Phosphorus | Calcium | Glucose | |
| Lovastatin 80 mg | 0.0 | 0.0 | -0.4 | 0.0 | 0.0 | -4.3 |
| Placebo | 0.1 | 0.0 | -0.5 | 0.0 | 0.0 | -1.2 |
29 reviews available for chloroquine and Rheumatism
| Article | Year |
|---|---|
COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Juvenile; Beta | 2020 |
Should coronavirus disease 2019 concern rheumatologists?
Topics: Antirheumatic Agents; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans | 2020 |
Interventions for treating patients with chikungunya virus infection-related rheumatic and musculoskeletal disorders: A systematic review.
Topics: Antirheumatic Agents; Chikungunya Fever; Chikungunya virus; Chloroquine; Humans; Hydroxychloroquine; | 2017 |
Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update.
Topics: Antirheumatic Agents; Chloroquine; Corneal Diseases; Dose-Response Relationship, Drug; Drug Administ | 2018 |
Are the Current Recommendations for Chloroquine and Hydroxychloroquine Screening Appropriate?
Topics: Antimalarials; Chloroquine; Eye Diseases; Humans; Hydroxychloroquine; Patient Care Management; Rheum | 2019 |
Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action.
Topics: Annexin A5; Antimalarials; Antiphospholipid Syndrome; Antirheumatic Agents; Cardiovascular Diseases; | 2011 |
Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature.
Topics: Antimalarials; Child; Chloroquine; Databases, Factual; Eye; Eye Diseases; Female; Humans; Hydroxychl | 2011 |
[Gastrointestinal side effects in the therapy of rheumatologic diseases].
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic | 2002 |
Plasma concentrations and therapeutic effect of anti-inflammatory and anti-rheumatic drugs.
Topics: Adrenal Cortex Hormones; Analgesics; Anti-Inflammatory Agents; Chloroquine; Gold; Humans; Penicillam | 1982 |
[Anti-inflammatory or antirheumatic agents? Pharmacological activity and therapeutic effectiveness of non-steroid anti-inflammatory drugs: comparative study. III].
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Autoimmune Diseases; Chloro | 1980 |
Recent developments in disease-modifying antirheumatic drugs.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Chloroquine; Gold; Humans; Immunosuppressive Agents | 1980 |
Antirheumatic drugs: clinical pharmacology and therapeutic use.
Topics: Adrenal Cortex Hormones; Analgesics; Anti-Inflammatory Agents; Antineoplastic Agents; Chloroquine; G | 1980 |
Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development.
Topics: Antigen Presentation; Antimalarials; Autoantigens; Autoimmune Diseases; Chloroquine; Drug Design; Hi | 1996 |
Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases.
Topics: Antirheumatic Agents; Biological Availability; Chloroquine; Drug Interactions; Humans; Hydroxychloro | 1996 |
Antimalarial drugs in the treatment of rheumatological diseases.
Topics: Antimalarials; Chloroquine; Contraindications; Female; Humans; Hydroxychloroquine; Male; Pregnancy; | 1997 |
[Interactions of antirheumatic agents].
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Anticoagulants; Anticonvulsants; Antihyperten | 1979 |
The mechanism of action of antirheumatic agents.
Topics: Acetylglucosaminidase; Adjuvants, Immunologic; Anti-Inflammatory Agents; Antineoplastic Agents; Arth | 1979 |
[Problems of basic therapy of rheumatic diseases with chloroquine, gold and D-penicillamine].
Topics: Aurothioglucose; Chloroquine; Gold; Gold Sodium Thiomalate; Humans; Hydroxychloroquine; Penicillamin | 1979 |
Miscellaneous antirheumatic drugs and their possible modes of action.
Topics: Animals; Bacteria; Cartilage, Articular; Chemotaxis, Leukocyte; Chloroquine; Collagen; Enzyme Inhibi | 1977 |
Antimalarials in rheumatic diseases.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lysosomes; Rheumat | 1990 |
Management of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Juvenile; Arthritis, Rheumatoid; Azathioprine; Chloroquine; Cyc | 1986 |
Antimalarials in rheumatology: efficacy and safety.
Topics: Antimalarials; Arthritis, Rheumatoid; Biomechanical Phenomena; Chloroquine; Clinical Trials as Topic | 1987 |
Antirheumatic drug treatment during pregnancy and lactation.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Azathioprine; Chloroquine; Cyc | 1985 |
Antirheumatic medication in pregnancy.
Topics: Abnormalities, Drug-Induced; Adrenal Cortex Hormones; Animals; Anti-Inflammatory Agents; Antineoplas | 1985 |
Ocular manifestations of rheumatic disorders. Natural and iatrogenic.
Topics: Adrenal Cortex Hormones; Arteritis; Arthritis, Juvenile; Arthritis, Rheumatoid; Chloroquine; Conjunc | 1973 |
Ocular complications in rheumatic disorders.
Topics: Arthritis, Rheumatoid; Cataract; Chloroquine; Conjunctivitis; Eye Diseases; Glaucoma; Humans; Iritis | 1973 |
An updated look at antirheumatic drugs.
Topics: Allopurinol; Anti-Inflammatory Agents; Arthritis; Azathioprine; Chloroquine; Cyclophosphamide; Gluco | 1967 |
[Amyloidosis in chronic rheumatic diseases].
Topics: Adult; Aged; Amyloidosis; Arthritis, Rheumatoid; Biopsy; Chloroquine; Chronic Disease; Collagen Dise | 1968 |
[Antirheumatic drugs. 40].
Topics: Aminopyrine; Analgesics; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antimalarials; Antipyrine; | 1969 |
5 trials available for chloroquine and Rheumatism
| Article | Year |
|---|---|
Use of microperimetry to evaluate hydroxychloroquine and chloroquine retinal toxicity.
Topics: Adult; Antirheumatic Agents; Chloroquine; Cross-Sectional Studies; Electroretinography; Female; Fixa | 2013 |
Therapy with statins in patients with refractory rheumatic diseases: a preliminary study.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Atorvastatin; Biomarkers; Blood Sedimentation; | 2003 |
Palindromic rheumatism: a response to chloroquine.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Chloroquine; Female; Humans; Male; Middle Aged; Rheum | 1991 |
Antimalarials in rheumatology: efficacy and safety.
Topics: Antimalarials; Arthritis, Rheumatoid; Biomechanical Phenomena; Chloroquine; Clinical Trials as Topic | 1987 |
[Follow-up of a course of intermittent rheumatism].
Topics: Adult; Aspirin; Chloroquine; Clinical Trials as Topic; Female; Follow-Up Studies; Humans; Hydrarthro | 1974 |
78 other studies available for chloroquine and Rheumatism
| Article | Year |
|---|---|
Access to chloroquine in patients with rheumatic and musculoskeletal diseases attending rheumatology outpatient clinics during the COVID-19 pandemic.
Topics: Ambulatory Care Facilities; Antirheumatic Agents; Chloroquine; COVID-19 Drug Treatment; Humans; Musc | 2021 |
Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Reposi | 2020 |
What is the role of rheumatologists in the era of COVID-19?
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimalarials; Azetidines; Betacoronavir | 2020 |
Navigating COVID-19 in the developing world.
Topics: Antirheumatic Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Delivery of He | 2020 |
COVID-19 and rheumatic musculoskeletal disease patients: infection rates, attitudes and medication adherence in an Irish population.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Attitude to Health; Biological Products; Chloroq | 2021 |
Chloroquine and hydroxychloroquine - safety profile of potential COVID-19 drugs from the rheumatologist's perspective.
Topics: Adult; Aged; Antirheumatic Agents; Chloroquine; COVID-19 Drug Treatment; Eye; Female; Humans; Hydrox | 2021 |
Chloroquine-induced cardiomyopathy: a reversible cause of heart failure.
Topics: Antimalarials; Cardiomyopathies; Chloroquine; Echocardiography; Electrocardiography; Female; Heart F | 2018 |
Comparison of different screening methods for chloroquine/hydroxychloroquine retinopathy: multifocal electroretinography, color vision, perimetry, ophthalmoscopy, and fluorescein angiography.
Topics: Adult; Aged; Antirheumatic Agents; Chloroquine; Color Perception Tests; Diagnostic Techniques, Ophth | 2012 |
The value of chloroquine in rheumatoid disease: a four-year study of continuous therapy.
Topics: Arthritis, Rheumatoid; Chloroquine; Humans; Rheumatic Diseases | 1957 |
[Chloroquine & rheumatoid diseases].
Topics: Arthritis, Rheumatoid; Chloroquine; Humans; Rheumatic Diseases | 1958 |
[Side-effects of antirheumatic drugs].
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Azoles; Chloroquine; Humans; Rheumatic Diseases; Sali | 1959 |
[Effect and significance of resochin in the treatment of chronic progressive rheumatism].
Topics: Arthritis; Arthritis, Rheumatoid; Chloroquine; Humans; Rheumatic Diseases | 1960 |
[Effect of chloroquine in chronic progressive rheumatism].
Topics: Arthritis; Arthritis, Rheumatoid; Chloroquine; Rheumatic Diseases | 1960 |
[On chloroquine therapy of chronic rheumatics].
Topics: Chloroquine; Humans; Rheumatic Diseases | 1961 |
[Results of resochin (chloroquine) therapy of patients with chronic progressive rheumatism].
Topics: Arthritis; Arthritis, Rheumatoid; Chloroquine; Rheumatic Diseases | 1960 |
[On differentiation and therapy of "predominantly allergic sialoses" (Rauch)].
Topics: Chloroquine; Collagen Diseases; Humans; Mikulicz' Disease; Rheumatic Diseases; Salivary Glands; Sial | 1962 |
[Diseases of the rheumatic type and therapeutic viewpoints].
Topics: Analgesics; Analgesics, Non-Narcotic; Antipyretics; Chloroquine; Gold; Phenylbutazone; Physical Ther | 1963 |
Structure-action relationship among drugs acting on connective tissues (anti-rheumatic agents).
Topics: Antirheumatic Agents; Chloroquine; Connective Tissue; Humans; Hydrocortisone; Phenylbutazone; Quinol | 1962 |
[The treatment of chronic rheumatismal polyarthritis by chloroquine].
Topics: Arthritis; Arthritis, Rheumatoid; Chloroquine; Rheumatic Diseases | 1961 |
[COMBINED CHLOROQUINE, ASPIRIN AND PREDNISONE THERAPY OF PROGRESSIVE CHRONIC RHEUMATISM].
Topics: Arthritis; Arthritis, Rheumatoid; Aspirin; Chloroquine; Humans; Prednisone; Rheumatic Diseases | 1963 |
HAEMATOLOGICAL SIDE-EFFECTS OF SOME ANTI-RHEUMATIC DRUGS.
Topics: Aminopyrine; Antirheumatic Agents; Aspirin; Blood Platelets; Chloroquine; Colchicine; Complement Fix | 1963 |
[TREATMENT OF RHEUMATISM WITH RESOCHIN].
Topics: Aspirin; Chloroquine; Humans; Phenylbutazone; Prednisolone; Rheumatic Diseases; Rheumatic Heart Dise | 1963 |
[INDICATIONS AND CONTRAINDICATIONS FOR CORTISOL DERIVATIVES IN CHRONIC RHEUMATIC DISEASES].
Topics: Adrenal Cortex Hormones; Chloroquine; Hydrocortisone; Phenylbutazone; Rheumatic Diseases | 1964 |
[EXPERIENCE WITH THE TREATMENT OF JOINT RHEUMATISM AT THE HIROSHIMA ATOMIC BOMB CASUALTY HOSPITAL].
Topics: Adolescent; Adrenocorticotropic Hormone; Betamethasone; Chloroquine; Geriatrics; Hospitals; Japan; N | 1963 |
OCULAR COMPLICATIONS OF DRUG TREATMENT OF RHEUMATIC DISORDERS.
Topics: Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Aspirin; Chloroquine; Corneal Ulcer; Drug | 1964 |
[STUDY ON POSSIBLE COLLATERAL EFFECTS OF TREATMENT WITH CHLOROQUINE].
Topics: Arthritis; Arthritis, Rheumatoid; Blood; Blood Protein Electrophoresis; Chloroquine; Drug Therapy; K | 1964 |
[ANTI-RHEUMATIC DRUGS AND ACUTE PHASE TESTS IN THE TREATMENT OF CHRONIC PROGRESSIVE RHEUMATISM].
Topics: Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Blood Proteins; Chloroquine; Drug Therapy; G | 1964 |
[DAMAGE DUE TO LONG-TERM THERAPY. 1. ANTIRHEUMATIC AGENTS].
Topics: Adrenal Cortex Hormones; Aminopyrine; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Chloro | 1964 |
[Value of resochin therapy of primary chronic rheumatism].
Topics: Chloroquine; Quinolines; Rheumatic Diseases; Uricosuric Agents | 1959 |
[The treatment of inflammatory rheumatism by antimalarials (chloroquine and hydroxychloroquine)].
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Rheumatic Diseases; Rheumatic Fever | 1960 |
[Therapeutic effects of chloroquine in children. In a case of malignant lupoerythemato visceritis and 2 cases of chronic rheumatism].
Topics: Chloroquine; Lupus Erythematosus, Systemic; Rheumatic Diseases | 1961 |
[Treatment of chronic inflammatory rheumatism with chloroquine and its derivatives].
Topics: Arthritis, Rheumatoid; Chloroquine; Chronic Disease; Humans; Rheumatic Diseases; Rheumatic Fever | 1961 |
[Clinical experiences with the prolonged treatment of rheumatic diseases with chloroquine diphosphate].
Topics: Chloroquine; Rheumatic Diseases | 1961 |
Factors associated with chloroquine-induced retinopathy in rheumatic diseases.
Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Body Weight; Case-Control Studies; Chloroquine; Fema | 2004 |
Factors associated with chloroquine-induced retinopathy in rheumatic diseases: comments on the article by Araiza-Casillas et al.
Topics: Antimalarials; Antirheumatic Agents; Body Height; Body Weight; Chloroquine; Humans; Retinal Diseases | 2004 |
Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients.
Topics: Adult; Aged; Antimalarials; Antirheumatic Agents; Biopsy; Chloroquine; Clinical Enzyme Tests; Electr | 2006 |
[Adverse effects of antirheumatics in children and adolescents].
Topics: Adolescent; Anti-Inflammatory Agents; Child; Chloroquine; Gold; Humans; Immunosuppressive Agents; Pe | 1984 |
The use of drugs in rheumatic diseases.
Topics: Analgesics; Anti-Inflammatory Agents; Aspirin; Aurothioglucose; Chloroquine; Colchicine; Gold Sodium | 1984 |
Drug prescription patterns for rheumatic disorders in Sweden.
Topics: Administration, Oral; Anti-Inflammatory Agents; Chloroquine; Drug Prescriptions; Drug Utilization; G | 1984 |
Pharmacologic actions of 4-aminoquinoline compounds.
Topics: Aminoquinolines; Cell Membrane; Chloroquine; Exocytosis; Half-Life; Hemin; Humans; Hydroxychloroquin | 1983 |
Steady state disposition of chloroquine in patients with rheumatoid disease.
Topics: Aged; Biotransformation; Chloroquine; Creatinine; Female; Humans; Middle Aged; Rheumatic Diseases | 1983 |
The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects.
Topics: Administration, Oral; Adult; Chloroquine; Chromatography, High Pressure Liquid; Female; Half-Life; H | 1984 |
On the question of interindividual variations in chloroquine concentrations.
Topics: Adult; Child; Chloroquine; Drug Monitoring; Humans; Malaria; Rheumatic Diseases | 1993 |
Possible mechanisms of action of antimalarials in rheumatic disease.
Topics: Cells; Chloroquine; Humans; Hydroxychloroquine; Kinetics; Rheumatic Diseases | 1993 |
Long-term effectiveness of antimalarial drugs in rheumatic diseases.
Topics: Adult; Antimalarials; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Chloroquine; Female; F | 1998 |
Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases.
Topics: Antirheumatic Agents; Child; Child, Preschool; Chloroquine; Female; Humans; Hydroxychloroquine; Infa | 2001 |
Chloroquine in rheumatic disease.
Topics: Chloroquine; Humans; Rheumatic Diseases | 1979 |
[Guidelines to the therapie of the most important rheumatic diseases (author's transl)].
Topics: Adrenocorticotropic Hormone; Anti-Inflammatory Agents; Chloroquine; Gold; Humans; Immunosuppressive | 1977 |
Action of various drugs with anti-inflammatory or anti-rheumatic properties on pleurisy due to Bordetella pertussis hypersensitivity in the rat.
Topics: Animals; Anti-Inflammatory Agents; Bordetella pertussis; Chloroquine; Cyclophosphamide; Desonide; In | 1979 |
[Problems of rheumatism therapy in pregnant women].
Topics: Abortion, Spontaneous; Chloroquine; Female; Gold; Humans; Hyperbilirubinemia; Indomethacin; Penicill | 1978 |
Chloroquine serum concentration and side effects: evidence for dose-dependent kinetics.
Topics: Adult; Aged; Chloroquine; Dose-Response Relationship, Drug; Female; Humans; Kinetics; Male; Middle A | 1979 |
Antirheumatic agents.
Topics: Adrenal Cortex Hormones; Antimalarials; Aspirin; Azathioprine; Chloroquine; Cyclophosphamide; Gold; | 1979 |
Symptomatic antirheumatic problems with the older patient: drug interactions.
Topics: Adrenal Cortex Hormones; Aged; Arthritis, Rheumatoid; Chloroquine; Drug Interactions; Humans; Middle | 1979 |
[Muscular changes in rheumatoid arthritis and other rheumatic disorders].
Topics: Arthritis, Rheumatoid; Chloroquine; Humans; Muscles; Muscular Diseases; Penicillamine; Rheumatic Dis | 1979 |
[Problems of rheumatic therapy in pregnancy (author's transl)].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Azathioprine; Chloroquine; Female; Fetal Diseases | 1976 |
[Cytogenetic effects of chloroquine in a culture of human lymphocytes].
Topics: Adult; Cells, Cultured; Chloroquine; Chromosome Aberrations; Humans; Lymphocytes; Mitosis; Rheumatic | 1976 |
D-penicillamine in palindromic rheumatism.
Topics: Chloroquine; Humans; Penicillamine; Periodicity; Rheumatic Diseases | 1976 |
[Drug therapy of most important rheumatic diseases].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Chloroquine; Gold; Humans; Penici | 1976 |
[Use of the resochin test in pediatric rheumatology].
Topics: Adolescent; Blood Proteins; Chemical Precipitation; Child; Child, Preschool; Chloroquine; Humans; Rh | 1989 |
Treatment of palindromic rheumatism with chloroquine.
Topics: Adult; Chloroquine; Humans; Male; Middle Aged; Recurrence; Rheumatic Diseases | 1987 |
Treatment of palindromic rheumatism with chloroquine.
Topics: Chloroquine; Humans; Rheumatic Diseases | 1987 |
[Eye findings in rheumatic diseases].
Topics: Adolescent; Arthritis, Juvenile; Arthritis, Reactive; Arthritis, Rheumatoid; Behcet Syndrome; Catara | 1974 |
Adverse reactions of antirheumatic drugs.
Topics: Analgesics; Anti-Inflammatory Agents; Chloroquine; Dimethylamines; Drug Hypersensitivity; Gold; Huma | 1973 |
Structural formulae of drugs commonly used in the treatment of rheumatic disease.
Topics: Alkylating Agents; Analgesics; Anti-Inflammatory Agents; Antineoplastic Agents; Chemical Phenomena; | 1973 |
[EOG-findings in resochin therapy (author's transl)].
Topics: Adult; Aged; Chloroquine; Electrooculography; Eye Diseases; Humans; Lupus Erythematosus, Systemic; M | 1973 |
[Antirheumatics and proteolytic enzymes (review)].
Topics: Anti-Inflammatory Agents; Chloroquine; Fibrinolysis; Humans; Hydrogen-Ion Concentration; Hydrolysis; | 1973 |
[Combination of aspirin, chloroquine and prednisone in rheumatology].
Topics: Arthritis, Rheumatoid; Aspirin; Chloroquine; Prednisone; Rheumatic Diseases | 1965 |
[4 Years of therapy with the antirheumatic agent Elestol].
Topics: Aspirin; Chloroquine; Humans; Prednisone; Rheumatic Diseases | 1966 |
[Dangers of the modern therapy for rheumatism].
Topics: Aminopyrine; Chloroquine; Female; Humans; Middle Aged; Penicillin G Benzathine; Phenylbutazone; Pred | 1966 |
Interrelationships of ophthalmology and rheumatic diseases.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Cataract; Chloroquine; Eye Diseases; Glaucoma; Human | 1968 |
[Critical view on drug therapy for rheumatism].
Topics: Analgesics; Animals; Anti-Bacterial Agents; Chloroquine; Drug-Related Side Effects and Adverse React | 1967 |
[Critic of rheumatism therapy in the practice].
Topics: Adrenal Cortex Hormones; Ambulatory Care; Arthritis, Rheumatoid; Chloroquine; Chronic Disease; Famil | 1967 |
[Antimalarial drugs as basic treatment of diffuse connective tissue diseases].
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Collagen Diseases; Humans; I | 1969 |
[Intra-articular nivaquine in rheumatology].
Topics: Adult; Chloroquine; Humans; Injections, Intra-Articular; Rheumatic Diseases | 1968 |
The development of an antirheumatic drug.
Topics: Adrenal Cortex Hormones; Analgesics; Animals; Anti-Inflammatory Agents; Aspirin; Cats; Chloroquine; | 1971 |
[Treatment of rheumatic eye diseases].
Topics: Adult; Chloroquine; Eye Diseases; Humans; Male; Rheumatic Diseases; Time Factors; Uveitis; Uveitis, | 1971 |
[Site and mode of action of antirheumatic agents].
Topics: Anti-Inflammatory Agents; Antigens; Antilymphocyte Serum; Arthritis, Rheumatoid; Chloroquine; Glucoc | 1971 |
[Dosage and adverse effects of commonly used antirheumatic agents].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Chloroquine; Drug Combinations; Glucocorticoids; Go | 1971 |